Eledon Pharmaceuticals (ELDN) EBIAT (2016 - 2017)
Historic EBIAT for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q1 2017 value amounting to -$3.9 million.
- Eledon Pharmaceuticals' EBIAT rose 6616.49% to -$3.9 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$30.4 million, marking a year-over-year increase of 2971.82%. This contributed to the annual value of -$36.2 million for FY2024, which is 6895.06% up from last year.
- Latest data reveals that Eledon Pharmaceuticals reported EBIAT of -$3.9 million as of Q1 2017, which was up 6616.49% from -$3.7 million recorded in Q4 2016.
- Eledon Pharmaceuticals' 5-year EBIAT high stood at -$3.7 million for Q4 2016, and its period low was -$13.5 million during Q2 2016.
- Moreover, its 5-year median value for EBIAT was -$7.7 million (2014), whereas its average is -$8.3 million.
- Per our database at Business Quant, Eledon Pharmaceuticals' EBIAT plummeted by 17357.13% in 2015 and then skyrocketed by 6616.49% in 2017.
- Quarter analysis of 5 years shows Eledon Pharmaceuticals' EBIAT stood at -$5.5 million in 2013, then dropped by 12.36% to -$6.2 million in 2014, then plummeted by 77.46% to -$11.0 million in 2015, then surged by 66.08% to -$3.7 million in 2016, then dropped by 3.45% to -$3.9 million in 2017.
- Its EBIAT was -$3.9 million in Q1 2017, compared to -$3.7 million in Q4 2016 and -$9.3 million in Q3 2016.